Walleye Capital
ARQT icon

Walleye Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Walleye Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66K Sell
2,800
-3,500
-56% -$89.3K ﹤0.01% 3815
2025
Q4 		$183K Buy
6,300
+1,300
+26% +$33.3K ﹤0.01% 3579
2025
Q3 		$94.3K Sell
5,000
-13,500
-73% -$213K ﹤0.01% 3733
2025
Q2 		$259K Buy
+18,500
New +$259K ﹤0.01% 3172

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital's ARQT Position: Q1 2026 in Review

Walleye Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 70% in Q1 2026, selling an estimated $3.02M and leaving 50,460 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1919.

Walleye Capital first reported a position in ARQT in Q4 2021 and has held it in 8 quarters since. The position peaked at $4.9M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Walleye Capital held 50,460 shares of Arcutis Biotherapeutics worth $1.19M as of Q1 2026.
  • Walleye Capital sold 118,144 Arcutis Biotherapeutics shares in Q1 2026, an estimated $3.02M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #1919 holding.
  • Walleye Capital first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 8 quarters since.
  • Walleye Capital's Arcutis Biotherapeutics position peaked at $4.9M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.